Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for the treatment of breast cancer

a breast cancer and treatment method technology, applied in the field of breast cancer treatment methods, can solve the problems of neoplastic disease states, serious and often life-threatening conditions, and limited benefit of additional conventional treatmen

Active Publication Date: 2019-03-12
SYNDAX PHARM INC
View PDF12 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cancer, tumors, tumor-related disorders, and neoplastic disease states are serious and often times life-threatening conditions.
If patients fail to respond to an aromatase inhibitor treatment, additional conventional treatment offers limited benefit.
Despite the approval of several aromatase inhibitors for the treatment of early and late stage breast cancer, as with most therapeutic agents, side-effects result from its use.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for the treatment of breast cancer
  • Methods for the treatment of breast cancer
  • Methods for the treatment of breast cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1a

[0155]A Phase 2, Randomized, Double-Blind, Study of Exemestane With and Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase Inhibitor

[0156]The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with exemestane in the treatment of advanced breast cancer.

[0157]Primary Outcome Measures are to compare the efficacy of exemestane alone with exemestane plus entinostat, as determined by the duration of progression free survival (PFS) measured from the date of randomization.

[0158]Secondary Outcome Measures are to compare objective response rate (ORR) and clinical benefit rate (CBR), and to evaluate the safety and tolerability of entinostat in combination with exemestane as measured by adverse events and laboratory safety parameters.

[0159]Study Design

[0160]

ArmAssigned Interventions1: ExperimentalDrug: entinostatexemestane (Aromasi...

example 1b

[0197]In a 23-month patient follow up of the study described above in Example 1a, a multicenter, randomized, double-blind, placebo-controlled, phase 2 study of exemestane with and without entinostat in 130 patients with locally recurrent or metastatic estrogen receptor-positive breast cancer, the median overall survival of exemestane plus entinostat patients reached 26.9 months versus 19.8 months for exemestane plus placebo. This represents a 42% reduction (p=0.04) in the risk of dying for these patients. Earlier data from this study demonstrated a near doubling in the progression-free survival (PFS) (4.3 vs. 2.3 months) with exemestane plus entinostat and the identification of a subset of these patients whose median PFS reached 8.5 months.

[0198]The conclusion is that after two years of follow up the patients treated with entinostat and exemestane benefited from an additional seven months of overall survival. This study illustrates not only a progression-free survival advantage (4.3...

example 1c

Confirmatory Phase 2 Study

[0204]The primary endpoint was progression-free survival (PFS). Peripheral blood mononuclear cells were collected in a subset of patients pre- and post-dose in cycle 1 for evaluation of protein lysine acetylation as a biomarker of entinostat activity (FIG. 11).

Patients and Methods

[0205]Study Design:

[0206]This was a Phase 2, randomized, double-blind, placebo-controlled study of exemestane±entinostat in patients with locally advanced or metastatic BC that had progressed on a NSAI (FIG. 12). One hundred thirty (130) patients were enrolled between June 2008 and July 2010 at 38 sites in North America, Central Europe, and Russia. All patients provided written informed consent. Patients were randomized in a 1:1 ratio using a blocked randomization scheme to exemestane plus entinostat (EE; n=64) or exemestane plus placebo (EP; n=66). Randomization was stratified by 1) prior NSAI treatment setting (adjuvant / metastatic); 2) metastases in bone only (yes / no); and 3) geo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.

Description

CROSS REFERENCE[0001]This application is a US national phase application under 35 USC § 371 of international application PCT / US2012 / 053551, filed Aug. 31, 2012; which claims the benefit of U.S. Provisional Application No. 61 / 568,110, filed Dec. 7, 2011; U.S. Provisional Application No. 61 / 628,999, filed Nov. 12, 2011; U.S. Provisional Application No. 61 / 532,534, filed Sep. 8, 2011; and U.S. Provisional Application No. 61 / 530,873, filed Sep. 2, 2011, each of which is incorporated herein by reference in its entirety.FIELD[0002]The present invention relates to methods for the treatment of breast cancer based on the administration HDAC inhibitors and aromatase inhibitors.BACKGROUND[0003]Cancer, tumors, tumor-related disorders, and neoplastic disease states are serious and often times life-threatening conditions. These diseases and disorders, which are characterized by rapidly-proliferating cell growth, continue to be the subject of research efforts directed toward the identification of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K31/566G01N33/483A61K31/5685A61K31/4406A61K31/4196A61K45/06A61P35/00
CPCA61K31/566A61K31/4196A61K31/4406A61K31/5685A61K45/06G01N33/4833A61P35/00G01N2800/52A61K2300/00A61P15/14A61P35/04A61P43/00A61P5/30
Inventor GOODENOW, ROBERTORDENTLICH, PETER
Owner SYNDAX PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com